BRAF and neoplasm: Among the assessed mutation variation, V600E accounts for nearly 90% of the B-RAF mutations, imparting a negative charge on the kinase domain of B-RAF, thereby resulting in constitutive MAPK signaling for tumor progression (Davies et al., 2002).